Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9LGV

Crystal structure of human PKMYT1 protein kinase domain with Naphthyridinone Inhibitor compound 11

This is a non-PDB format compatible entry.
Summary for 9LGV
Entry DOI10.2210/pdb9lgv/pdb
Related9LGL 9LGN
DescriptorMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase, L(+)-TARTARIC ACID, 3-azanyl-7-chloranyl-4-(7-fluoranyl-1H-indazol-4-yl)-1H-1,5-naphthyridin-2-one, ... (5 entities in total)
Functional Keywordsinhibitor, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight65036.43
Authors
Xu, Z.H.,Chen, S. (deposition date: 2025-01-10, release date: 2025-04-16)
Primary citationChen, B.,Liu, X.,Mu, T.,Xu, J.,Zhao, D.,Dey, F.,Tang, Y.,Xu, Z.,Yang, J.,Huang, K.,Li, C.,Chen, S.,Zhu, S.,Wang, S.,Yao, X.,Yan, Z.,Tu, Y.,Dai, Y.,Qiu, H.,Yang, J.,Jiang, T.,Qi, Y.,Li, Y.,Shen, H.C.,Zhu, W.,Tan, X.,Wu, J.
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy.
J.Med.Chem., 2025
Cited by
PubMed Abstract: PKMYT1 is a crucial regulator of the cell cycle, particularly involved in the G2/M transition through the inhibitory phosphorylation of CDK1, and is a promising therapeutic target for cancer therapy. Data mining in the Roche kinome screen database identified a hit characterized by 100% PKMYT1 inhibitory activity at a 10 μM concentration, which was further validated with a PKMYT1 enzymatic assay showing double-digit nanomolar potency. The hit featured a quinolinone central core and a phenol headgroup. The replacement of the problematic phenol headgroup with an indazole moiety induced a flip in the kinase hinge cysteine and glycine residues, resulting in a series of derivatives with enhanced potency, superior kinome selectivity, and no GSH flag. Further structural fine-tuning led to the discovery of compound , a novel, selective, and potent PKMYT1 inhibitor with favorable oral pharmacokinetic profiles and promising in vivo antitumor efficacy.
PubMed: 40198752
DOI: 10.1021/acs.jmedchem.5c00114
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.041 Å)
Structure validation

235458

PDB entries from 2025-04-30

PDB statisticsPDBj update infoContact PDBjnumon